America's Drug Industry Has a New Problem. Someone Must Now Check Where the Money Goes.
- For
- Employer benefit-plan fiduciaries, benefits procurement teams, audit/software providers and investors researching pharmacy economics.
- Where
- United States: large self-insured ERISA group health plans, not all insurance or every pharmacy transaction.
- What it means
New pharmacy disclosures could create demand for checking money flows, alongside buying medicines and negotiating benefits.
- Why it matters
Employers gain audit rights, while Cigna’s pharmacy revenue growth has not translated into higher segment operating income.
- What to do
Check paid audit contracts, employer procurement and supplier margins before assuming consultants or software vendors will benefit.
- What we don't know
External spending, recoverable savings and employee benefits remain unproven. Audits are optional, so existing internal checks could satisfy demand.
- Urgency
- Not assessed
- No urgency assessment has been entered.
First published